CSI Market
Sign In | Register

Paratek Pharmaceuticals Inc (PRTK) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PRTK quarterly Cash Flow →
The table below presents a historical view of Paratek Pharmaceuticals Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2018)
Operating Activities
Income-63.57
Depreciation & amortization0.49
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-9.09
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Other Assets0.00
Share-based Compensation12.32
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest5.41
Amortization Of Lease Liability-
Remeasurement Of Preferred Stock Warrants-
Gain Loss On Issuance Of Convertible Notes-
Gain Loss On Issuance Of Equity Associated With Convertible Notes-
Gain Loss On Exchange Of Nonconvertible Notes For Common Stock-
Increase Decrease In Operating Lease Right Of Use Asset-0.03
Employee Benefits And Share Based Compensation Noncash-
Gains Losses On Extinguishment Of Debt Non Cash Portion-
Increase Decrease Accounts Receivable Other Receivables Prepaid Expenses And Other Current Assets-40.42
Increase Decrease In Long Term Operating Lease Liability-
Increase Decrease In Operating Lease Liability0.16
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities7.68
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Interest0.00
Other Working Capital-2.57
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities23.48
Discontinued operations0.00
Net Cash flow from Operating Activities-66.14
Investing Activities
Capital Expenditures-0.04
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities30.00
Payments to Acquire Available-for-sale Securities, Debt-15.16
Real Estate Investments0.00
Cash And Cash Equivalents Received From Merger-
Payments To Acquire Prepaid Interest Marketable Securities-
Proceeds From Maturities Of Marketable Securities-
Proceeds From Sales Of Marketable Securities-
Decrease in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Sale of Finance Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities14.80
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-2.89
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock7.98
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Non Convertible Note-
Proceeds From Issuance Of Convertible Note-
Refund Of Prefunding For Financing-
Issuance Of Convertible Preferred Stock Value-
Proceeds From Non Convertible Note Financing-
Refund Payment Or Prefunding Proceeds From Financing-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.09
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-66.18
Total Cash Flow-46.24
4 historic quarters locked

Sign in to unlock the full Paratek Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Paratek Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-23-027035

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License